The 620 basis point gross margin contraction over six quarters suggests that cost inflation, particularly in labor, is outpacing reimbursement rate updates. Operating margin followed a similar trajectory, declining from 17.8% to 13.2% over the same period, indicating negative operating leverage. This margin erosion appears structural rather than transient, as it persisted despite revenue growth, and may reflect a fundamental shift in the cost environment for hospice care.

The decline in ROIC from 7.7% to 6.1% over six quarters suggests that the company is generating less return on its invested capital, driven by margin compression rather than asset efficiency. ROE has been more volatile, dipping to 4.4% in 2025Q2 before recovering to 8.1% in 2026Q2, but the overall trend points to a lower return profile. This may indicate that the company's competitive advantages are being eroded by cost pressures, and investors should monitor whether management can restore margins to prior levels.

The improvement in the cash conversion cycle from 26 to 17 days over the past year suggests that Chemed is managing its working capital more efficiently, particularly in collecting receivables. DSO declined from 35 days in 2025Q2 to 27 days in 2026Q2, which may reflect better billing processes or a shift in revenue mix toward Roto-Rooter's transactional services. However, DPO has remained relatively stable around 10-12 days, indicating limited supplier leverage, and the overall efficiency gains appear modest.

The increase in D/E from 0.12 to 0.40 over the past two years represents a significant shift from the company's historically conservative balance sheet, though the absolute level remains low. Interest coverage of 47.2x in 2026Q2 suggests that debt service is still very comfortable, but the trend warrants monitoring. The debt accumulation appears to be funding share repurchases, which have reduced equity, and investors should assess whether this leverage is being used to create value or simply to support the stock price.

The current ratio falling below 1.0 suggests that Chemed's current liabilities now exceed its current assets, a notable shift from the comfortable liquidity position of 2024. The decline in cash from $313.4M to $40.2M over the same period highlights the impact of aggressive buybacks and debt accumulation. While the company's cash flow generation remains positive, the thin liquidity buffer could become a concern if working capital needs spike or if a downturn affects cash collections.